A more recent multi-institutional study found no significant differences between upfront RT + TKI vs. TKI alone for patients with EGFR- and ALK-positive NSCLC, suggesting that RT can be deferred during the progression of the disease [59]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.